Oxford University Press

SHERPA: Yellow

People

  1. Drilon
    Drilon
  2. Motzer
    Motzer
  3. Mellinghoff
    Mellinghoff
  4. Shuman
    Shuman
  5. Rosenblum
    Rosenblum
  6. Dunkel
    Dunkel
  7. Karajannis
    Karajannis
  8. Saltz
    Saltz
  9. Souweidane
    Souweidane
  10. Panageas
    Panageas

Groups

  1. Department of Medicine (1995)
  2. Solid Tumor Oncology Division (1624)
  3. GSK Faculty (765)
  4. Survivorship Research (639)
  5. Population Sciences Research Program (615)
  6. Epidemiology and Biostatistics (465)
  7. Department of Pathology and Laboratory Medicine (415)
  8. Gastrointestinal Oncology Service (386)
  9. Genitourinary Oncology Service (367)
  10. Tow Center for Developmental Oncology (TCDO) (352)
Search Within
Formats
  1. Journal Article (2107)
  2. Meeting Abstract (2072)
  3. Book Section (192)
  4. Review (92)
  5. Editorial (84)
  6. Guidelines (36)
  7. Correspondence (26)
  8. Book Whole (18)
  9. Conference Paper (15)
  10. Research Letter (10)
Groups
  1. Department of Medicine (1995)
  2. Solid Tumor Oncology Division (1624)
  3. GSK Faculty (765)
  4. Survivorship Research (639)
  5. Population Sciences Research Program (615)
  6. Epidemiology and Biostatistics (465)

More Groups

People
  1. Lisa De Angelis (119)
  2. Alexander Drilon (108)
  3. Robert Motzer (96)
  4. Ingo Mellinghoff (93)
  5. Stewart Shuman (88)
  6. Marc Rosenblum (87)

More People

Years
  1. 2025 (105)
  2. 2024 (304)
  3. 2023 (320)
  4. 2022 (331)
  5. 2021 (323)
  6. 2020 (325)

More Years

Publications
  1. Annals of Oncology (1670)
  2. Neuro-Oncology (846)
  3. JNCI: Journal of the National Cancer Institute (485)
  4. Nucleic Acids Research (210)
  5. Clinical Infectious Diseases (138)
  6. American Journal of Clinical Pathology (106)

More Publications

Results (4652)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase (Ph) II study of zanidatamab + chemotherapy (chemo) in first-line (1L) HER2 expressing gastroesophageal adenocarcinoma (GEA)
    Meeting Abstract

    Ku, G.; Elimova, E.; Denlinger, C. S.; Mehta, R.; Lee, K. W.; Iqbal, S.; Kang, Y. K.; Oh, D. Y.; Rha, S. Y.; Kim, Y. H.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Genomic landscape of late-stage gastric cancer
    Meeting Abstract

    Janjigian, Y. Y.; Cecchini, M.; Shitara, K.; Enzinger, P. C.; Wainberg, Z. A.; Catenacci, D. V.; Chau, I.; Satoh, T.; Lee, J.; Loboda, A.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • EGFR inhibition in EGFR-amplified esophagogastric cancer (EGC): Retrospective global experience
    Meeting Abstract

    Maron, S.; Moya, S.; Morano, F.; Emmett, M. J.; Disel, U.; Chalasani, S.; Ku, G.; Kasi, P. M.; Uboha, N.; Kato, S.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • MOUNTAINEER-02: Phase II/III study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+ gastric or gastroesophageal junction adenocarcinoma (GEC): Trial in progress
    Meeting Abstract

    Catenacci, D. V.; Strickler, J. H.; Shitara, K.; Nakamura, Y.; Janjigian, Y. Y.; Barzi, A.; Bekaii-Saab, T.; Lenz, H. J.; Chung, H. C.; Tabernero, J.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Health utility with tepotinib in patients (pts) with MET exon 14 (METex14) skipping non-small cell lung cancer (NSCLC)
    Meeting Abstract

    Reinmuth, N.; Popat, S.; Paz-Ares, L.; Knowles, E.; Hatswell, A.; McLean, T.; Adrian, S.; Gaumond, B.; Vioix, H.; Paik, P. K.
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Early circulating tumour DNA (ctDNA) dynamics for predicting and monitoring response to immunotherapy (IO) vs chemotherapy (CT) in patients with 1L metastatic (m) NSCLC: Analyses from the phase III MYSTIC trial
    Meeting Abstract

    Peters, S.; Rizvi, N. A.; Kuziora, M.; Lai, Z.; Shrestha, Y.; Dey, A.; Barrett, J. C.; Scheuring, U.; Poole, L.; Abbosh, C.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Genomic alterations of bone metastases in stage IV non-small cell lung cancer (NSCLC) and real-world outcomes
    Meeting Abstract

    Voon, P. J.; Riely, G. J.; Lepisto, E. M.; Lavery, J. A.; Warner, J. L.; LeNoue-Newton, M. L.; Sweeney, S. M.; McCarthy, C. G.; Samantha, B.; Panageas, K. S.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-mutated (HER2m) metastatic non-small cell lung cancer (NSCLC): A phase (ph) II study (DESTINY-Lung02)
    Meeting Abstract

    Smit, E. F. F.; Li, B. T.; Mazieres, J.; Planchard, D.; Nakagawa, K.; Goto, K.; Paz-Ares, L.; Novello, S.; Yang, J. C. H.; Ahn, M. J.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Characterization and management of mobocertinib (TAK-788) induced skin toxicity in patients with EGFR exon 20 insertion+ (ex20ins+) non-small cell lung cancer (NSCLC) who previously received platinum chemotherapy
    Meeting Abstract

    Yang, J. C. H.; Ramalingam, S. S.; Kim, T. M.; Kim, S. W.; Riely, G. J.; Mekhail, T.; Nguyen, D.; Garcia Campelo, M. R.; Felip, E.; Bazhenova, L.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • ORCHARD osimertinib + savolitinib interim analysis: A biomarker-directed phase II platform study in patients (pts) with advanced non-small cell lung cancer (NSCLC) whose disease has progressed on first-line (1L) osimertinib
    Meeting Abstract

    Yu, H. A.; Ambrose, H.; Baik, C.; Cho, B. C.; Cocco, E.; Goldberg, S. B.; Goldman, J. W.; Kraljevic, S.; de Langen, A. J.; Okamoto, I.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save